Neurotech International Limited announced that it has appointed Dr. Thomas Duthy from Nemean Group Pty Ltd. as a consultant to the Company with a focus on Investor Relations (IR) and Strategic Corporate Development. The company's Board has made a commitment to appoint Dr. Thomas Duthy as an Executive Director, to assist the Company in this capacity effective 1 September 2022. Concurrently, current Non-Executive Director Mark Davies, has been appointed as Chairman of the Board.

Mr. Davies succeeds Brian Leedman who along with Krista Bates have resigned from their positions on the Board to pursue other corporate interests, effective immediately. In addition to the above changes, current Non-Executive Directors Professor Allan Cripps will be appointed as Director of Science and Innovation and Gerald Quigley will be appointed as Director of Public Relations. Dr. Duthy will be engaged via a service company (Nemean Group Pty Ltd) to provide those services usually required of an Executive Director of a Company of the nature and scale of NTI with a focus on Investor Relations and Strategic Corporate Development.